Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 7/20 | 0.39 |
| ▸ | FNTB | P49356 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254761 | 0.91 | ALOX15 (0.54) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL8466948 | 0.91 | ALOX15 (0.54) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL20839197 | 0.89 | ALOX15 (0.57) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL30883182 | 0.87 | ALOX15 (0.55) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL9017160 | 0.85 | ALOX15 (0.59) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL22372389 | 0.85 | ALOX15 (0.59) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL22372388 | 0.85 | ALOX15 (0.59) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL2004080 | 0.85 | ALOX15 (0.59) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL3506100 | 0.85 | ALOX15 (0.59) | ALOX15KMT2AALDH1A1FNTAFNTB | |
| SCHEMBL9017126 | 0.85 | ALOX15 (0.59) | ALOX15KMT2AALDH1A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | ALOX15 1698/4885KMT2A 3588/4885ALDH1A1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.